Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Relugolix Induces Similar Rates of Castration Resistance–Free Survival Vs Leuprolide in Advanced Prostate Cancer

September 11th 2021

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

Sequential Crizotinib Followed by Alectinib Associated With Survival Benefit in ALK+ NSCLC

September 11th 2021

Frontline sequential therapy with crizotinib followed by alectinib demonstrated survival benefits for patients with ALK-positive non–small cell lung cancer who develop resistance to, or become intolerant of crizotinib.

Ide-Cel Maintains Clinical Activity With Long-Term Follow-Up in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Sotorasib Induces Intracranial Activity in KRAS G12C–Mutated NSCLC Brain Metastases

September 8th 2021

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

September 5th 2021

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

MYLOX-1 Trial Opens to Evaluate Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

September 3rd 2021

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

New SITC Guidelines Provide First Recommendations for Immunotherapy in TNBC

September 2nd 2021

Following the integration of immunotherapy into the treatment paradigm of triple-negative breast cancer, a multidisciplinary panel of experts, brought together by the Society for Immunotherapy of Cancer, published the first clinical practice guidelines focused on navigating clinical decisions with immunotherapy in breast cancer.

Emerging Options Open the Door to Optimized Treatment Opportunities in Hematologic Malignancies

September 1st 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

Prior Treatment Confers Reduced Responses With Adoptive Transfer of TIL Therapy in Metastatic Melanoma

August 26th 2021

Prior treatment with PD-1 or MAPK inhibitors resulted in lower objective response rates with adoptive cell transfer of autologous tumor-infiltrating lymphocytes in patients with metastatic melanoma vs patients who were naïve to these agents.

Clinicopathologic and Genomic Testing Confirm Differences in Pediatric Melanocytic Tumors

August 24th 2021

Distinct subgroups of pediatric melanocytic lesions, which were identified by an integrated clinicopathologic and genomic analysis, were found to have different clinical behaviors, suggesting that this combined diagnostic modality could inform individualized diagnoses and treatments for patients with these rare malignancies.

MRD Negativity Moves Into the Spotlight as a Potential Surrogate End Point in Multiple Myeloma

August 23rd 2021

Ongoing research efforts are pushing to establish minimal residual disease negativity as a surrogate end point for patient outcomes in multiple myeloma clinical trials, and MRD assessment is becoming an increasingly utilized tool to inform real-world clinical decisions.

Clonal Hematopoiesis Confers Substantial Risks in Healthy Individuals and Patients with Cancer

August 20th 2021

Peter G. Miller, MD, PhD, discusses the characteristics and risks associated with clonal hematopoiesis and risk-stratification efforts for patients with cancer who are at risk of developing therapy-related secondary malignancies from clonal hematopoiesis.

New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma

August 16th 2021

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

Expanding Armamentarium Allows for Tailored Approaches in Breast Cancer, in Especially Older Patients

August 12th 2021

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Early Screening for Colorectal Neoplasia and Cancer Is Critical Among Younger Individuals

August 11th 2021

Steven H. Itzkowitz, MD, discusses the importance of screening for CRC in younger adults, the results of the database analysis, and strategies for implementing early messaging in the community setting for this population.

Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies

August 9th 2021

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

Optimal Sequencing and Treatment Intensity Remain the Focus of Treatment in HER2+ Breast Cancer

August 3rd 2021

G. Thomas Budd, MD, discussed the promise of tailored treatment approaches in HER2-positive breast cancer, the utility of the combination of fixed-dose trastuzumab, pertuzumab, and hyaluronidase-zzxf via subcutaneous administration, and how sequencing could be further affected by drug development.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

August 2nd 2021

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Imetelstat Elicits Efficacy Across Molecularly Defined Subgroups of Lower-Risk MDS

August 2nd 2021

Treatment with imetelstat demonstrated clinical efficacy across molecularly defined subgroups of patients with heavily transfused, lower-risk myelodysplastic syndrome who did not harbor 5q deletions and were relapsed/refractory to erythropoiesis-stimulating agents.